Labyrinthitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LBY004 MIFTS: 41	Labyrinthitis Categories: Ear diseases, Infectious diseases, Neuronal diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Labyrinthitis

MalaCards integrated aliases for Labyrinthitis:

Name: Labyrinthitis ¹² ⁷⁶ ⁴⁴ ¹⁵ ⁷³

Labyrinthine Disorder ⁷³

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Ear diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the ear and mastoid process

Diseases of inner ear

Other diseases of inner ear

Labyrinthitis

External Ids:

Disease Ontology ¹² DOID:1468

ICD10 ³³ H83.0 H83.09

ICD9CM ³⁵ 386.3 386.30

MeSH ⁴⁴ D007762

SNOMED-CT ⁶⁸ 155239008 194363004 194367003 more

UMLS ⁷³ C0022893

Sources

Summaries for Labyrinthitis

Disease Ontology : ¹² An otitis interna which involves inflammation of the labyrinths.

MalaCards based summary : Labyrinthitis, also known as labyrinthine disorder, is related to purulent labyrinthitis and focal labyrinthitis, and has symptoms including earache and vertigo. An important gene associated with Labyrinthitis is CRLF1 (Cytokine Receptor Like Factor 1). The drugs Betahistine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : ⁷⁶ Labyrinthitis, also known as vestibular neuritis, is the inflammation of inner ear. It results in a... more...

Sources

Related Diseases for Labyrinthitis

Diseases in the Labyrinthitis family:

Viral Labyrinthitis

Diseases related to Labyrinthitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)

#	Related Disease	Score
1	purulent labyrinthitis	12.3
2	focal labyrinthitis	12.3
3	viral labyrinthitis	12.3
4	toxic labyrinthitis	12.2
5	serous labyrinthitis	12.1
6	bilateral hyperactive labyrinth	11.9
7	unilateral hyperactive labyrinth	11.9
8	bilateral hypoactive labyrinth	11.9
9	unilateral hypoactive labyrinth	11.8
10	inner ear disease	11.7
11	meniere disease	11.2
12	vestibular neuronitis	10.9
13	meningitis	10.3
14	otitis media	10.3
15	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus	10.2
16	mastoiditis	10.1
17	sensorineural hearing loss	10.0
18	suppurative otitis media	10.0
19	aging	10.0
20	mumps	10.0
21	otosclerosis	9.9
22	sudden sensorineural hearing loss	9.9
23	pneumococcal meningitis	9.9
24	thrombosis	9.8
25	facial paralysis	9.8
26	auditory system disease	9.8
27	cerebritis	9.8
28	pneumonia	9.8
29	influenza	9.8
30	herpes simplex	9.8
31	autoimmune inner ear disease	9.8
32	congenital cytomegalovirus	9.8
33	headache	9.8
34	endotheliitis	9.8
35	osteoporosis	9.7
36	paragangliomas 1	9.7
37	torticollis	9.7
38	retinitis pigmentosa-deafness syndrome	9.7
39	macular degeneration, age-related, 1	9.7
40	anorexia nervosa	9.7
41	wegener granulomatosis	9.7
42	malaria	9.7
43	kawasaki disease	9.7
44	ulcerative colitis	9.7
45	usher syndrome	9.7
46	colitis	9.7
47	migraine with aura	9.7
48	osteomyelitis	9.7
49	petrositis	9.7
50	sarcoma	9.7

Comorbidity relations with Labyrinthitis via Phenotypic Disease Network (PDN): (show all 22)

Anxiety	Basilar Artery Insufficiency
Benign Essential Hypertension	Bronchitis
Cerebrovascular Disease	Chronic Myocardial Ischemia
Esophagitis	Generalized Atherosclerosis
Hypertension, Essential	Hypothyroidism
Inner Ear Disease	Intermediate Coronary Syndrome
Ischemic Heart Disease	Meniere Disease
Otitis Media	Pathologic Nystagmus
Peripheral Vertigo	Transient Cerebral Ischemia
Vertebral Artery Insufficiency	Vertigo, Benign Recurrent
Vestibular Nystagmus	Viral Labyrinthitis

Graphical network of the top 20 diseases related to Labyrinthitis:

Sources

Symptoms & Phenotypes for Labyrinthitis

UMLS symptoms related to Labyrinthitis:

earache, vertigo

GenomeRNAi Phenotypes related to Labyrinthitis according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-143	9.17	IGBP1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-208	9.17	IGBP1 NCS1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	9.17	NCS1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.17	IGBP1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.17	IGBP1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	9.17	NCS1

Sources

Drugs & Therapeutics for Labyrinthitis

Drugs for Labyrinthitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Betahistine

Approved, Investigational

Phase 4,Not Applicable

5638-76-6

2366

Histamine

Approved, Investigational

Phase 4,Phase 3,Not Applicable

75614-87-8, 51-45-6

774

Dimenhydrinate

Approved

Phase 4,Phase 3

523-87-5

441281

Piracetam

Approved, Investigational

Phase 4

7491-74-9

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Calcium Carbonate

Approved, Investigational

Phase 4

471-34-1

Ethanol

Approved

Phase 4

64-17-5

702

Glycerol

Approved, Investigational

Phase 4

56-81-5

753

Phenol

Approved, Experimental

Phase 4,Not Applicable

108-95-2

996

Thymol

Approved

Phase 4

89-83-8

6989

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

50-24-8

5755

Betamethasone

Approved, Vet_approved

Phase 4

378-44-9

9782

Glucosamine

Approved, Investigational, Nutraceutical

Phase 4

3416-24-8

439213

Caffeine

Approved, Nutraceutical

Phase 4

58-08-2

2519

Ergocalciferol

Approved, Nutraceutical

Phase 4

50-14-6

5280793

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4

67-97-0

6221 5280795

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3

59-30-3

6037

Niacin

Approved, Investigational, Nutraceutical

Phase 4

59-67-6

938

Nicotinamide

Approved, Investigational, Nutraceutical

Phase 4

98-92-0

936

Tocopherol

Approved, Investigational, Nutraceutical

Phase 4

1406-66-2

14986

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 4

59-02-9

14985

Anticoagulants

Phase 4

Antimetabolites

Phase 4,Phase 3

Fibrinolytic Agents

Phase 4

Glucuronyl glucosamine glycan sulfate

Phase 4

Hypoglycemic Agents

Phase 4

Hypolipidemic Agents

Phase 4

Lipid Regulating Agents

Phase 4

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 4,Phase 2

Histamine Phosphate

Phase 4,Phase 3,Not Applicable

51-74-1

65513

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Vasodilator Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Central Nervous System Stimulants

Phase 4

Phosphodiesterase Inhibitors

Phase 4,Phase 2,Not Applicable

Purinergic P1 Receptor Antagonists

Phase 4

Antiemetics

Phase 4,Phase 2,Phase 3,Not Applicable

Autonomic Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Gastrointestinal Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Histamine Antagonists

Phase 4,Phase 3,Not Applicable

Histamine H1 Antagonists

Phase 4,Phase 3,Not Applicable

Dopamine Agents

Phase 4

Dopamine Antagonists

Phase 4

Dopamine D2 Receptor Antagonists

Phase 4

Antacids

Phase 4,Phase 1,Phase 2

Anti-Ulcer Agents

Phase 4,Phase 1,Phase 2

Bone Density Conservation Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 177)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients	Unknown status	NCT00132223	Phase 4	Contrast agent
2	Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets	Completed	NCT02718846	Phase 4	Meniace;Isobide
3	Efficacy of Local Overpressure Treatment for Meniere's Disease	Completed	NCT00831688	Phase 4
4	Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy	Completed	NCT00160238	Phase 4	Betahistine 24 mg bid (Betaserc)
5	Effect of Caffeine Intake in Vestibular Function	Completed	NCT02825199	Phase 4
6	Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo	Completed	NCT01890538	Phase 4	Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
7	Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo	Completed	NCT02253524	Phase 4	Dimenhydrinate;Metoclopramide
8	Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV	Completed	NCT02031692	Phase 4	400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
9	Effect of Stellate Ganglion Block on Meniere's Disease	Completed	NCT01574313	Phase 4	0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
10	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal	Completed	NCT00765635	Phase 4	drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
11	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease	Recruiting	NCT02530931	Phase 4	Gadolinium
12	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)	Recruiting	NCT02529475	Phase 4	Gadoteric acid
13	Acute Unilateral Vestibulopathy and Corticosteroid Treatment	Recruiting	NCT02912182	Phase 4	Betamethasone;Placebo;Prednisolone
14	A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation	Withdrawn	NCT00474409	Phase 4	Merislon
15	Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease	Unknown status	NCT01729767	Phase 2, Phase 3	Acyclovir;Placebo
16	Conventional Versus Virtual Reality Based Vestibular Rehabilitation	Completed	NCT01442623	Phase 2, Phase 3
17	Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Completed	NCT02612337	Phase 3	OTO-104;Placebo
18	Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease	Completed	NCT01454726	Phase 3
19	Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease	Completed	NCT00802529	Phase 2, Phase 3	Methylprednisolone;Gentamicin
20	Study of Lamotrigine to Treat Ménière's Disease	Completed	NCT02158585	Phase 3	Lamotrigine;Placebo
21	The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo	Completed	NCT02029508	Phase 3
22	Promethazine vs. Lorazepam for Treatment of Vertigo	Completed	NCT01827293	Phase 3	Promethazine;Lorazepam
23	Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT01366430	Phase 3
24	Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT00810641	Phase 3
25	Canalith Repositioning Procedure for BPPV in Primary Care	Completed	NCT00182273	Phase 3
26	Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria	Completed	NCT00785135	Phase 3
27	Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin	Recruiting	NCT02112578	Phase 3	Meclizine;Dimenhydrinate
28	Rizatriptan for Episodic Dizziness in Vestibular Migraine	Recruiting	NCT02447991	Phase 2, Phase 3	Rizatriptan;Placebo
29	Caroverin and Inner Ear Diseases	Suspended	NCT01174979	Phase 3	Caroverin
30	Autoimmunity in Inner Ear Disease	Terminated	NCT00000361	Phase 3	Corticosteroids;Methotrexate
31	A 6-Month Extension Study of OTO-104 in Meniere's Disease	Terminated	NCT02768662	Phase 3	OTO-104
32	Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Terminated	NCT02717442	Phase 3	OTO-104;Placebo
33	A 6-Month Extension Study of OTO-104 in Meniere's Disease	Terminated	NCT02706730	Phase 3	OTO-104
34	Famvir for Treatment of Hearing in Unilateral Meniere's Disease	Terminated	NCT01526408	Phase 3	Famciclovir;Placebo
35	Latanoprost for the Treatment of Menière's Disease	Unknown status	NCT01973114	Phase 2	Latanoprost
36	Visual Feedback Goggle for Positional Vertigo Treatment	Unknown status	NCT00729885	Phase 1, Phase 2
37	Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy	Unknown status	NCT02247648	Phase 2	tramadol;Placebo
38	The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease	Completed	NCT01950312	Phase 2	gevokizumab
39	A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease	Completed	NCT01267994	Phase 1, Phase 2	Anakinra
40	Study to Evaluate SPI-1005 in Adults With Meniere's Disease	Completed	NCT02603081	Phase 1, Phase 2	SPI-1005
41	A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom	Completed	NCT02265393	Phase 2	OTO-104;Placebo
42	OTO-104 for the Treatment of Meniere's Disease	Completed	NCT01412177	Phase 2	OTO-104;Placebo
43	Sildenafil For Meniere's Disease	Completed	NCT00145483	Phase 2	Sildenafil
44	A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo	Completed	NCT02299804	Phase 2	Levophencynonate Hydrochloric;Placebo
45	Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT02046980	Phase 2
46	Effect of V0251 in Acute Vertigo	Completed	NCT01583738	Phase 2	V0251;placebo
47	Prednisone Treatment for Vestibular Neuronitis	Completed	NCT00271791	Phase 2	Prednisone;Prednisone
48	Treatments for Benign Paroxysmal Positional Vertigo (BPPV)	Completed	NCT00000359	Phase 2
49	A Trial of Booklet Based Self Management of Dizziness	Completed	NCT00732797	Phase 2
50	SPI-1005 for the Treatment of Patients With Meniere's Disease	Enrolling by invitation	NCT03325790	Phase 2	200mg SPI-1005 BID;400mg SPI-1005 BID

Search NIH Clinical Center for Labyrinthitis

Cochrane evidence based reviews: labyrinthitis

Sources

Genetic Tests for Labyrinthitis

Sources

Anatomical Context for Labyrinthitis

MalaCards organs/tissues related to Labyrinthitis:

⁴¹

Eye, Testes, Brain, Bone, Liver, Pons, Kidney

Sources

Publications for Labyrinthitis

Articles related to Labyrinthitis:

(show top 50) (show all 254)

#	Title	Authors	Year
1	Labyrinthitis Ossificans in a Cynomolgus Macaque (Macaca fascicularis). ( 29650059 )	Balamayooran G....Caudell D.L.	2018
2	Cochlear Implant Associated Labyrinthitis: A Previously Unrecognized Phenomenon With a Distinct Clinical and Electrophysiological Impedance Pattern. ( 29065095 )	Itayem D.A....Carlson M.L.	2017
3	Kawasaki Disease and Labyrinthitis: An Underdiagnosed Complication. ( 28417110 )	Kim K.Y....Seo Y.J.	2017
4	Does Otosclerosis Affect Dark and Transitional Cells in the Human Vestibular Labyrinth? ( 27851656 )	Kaya S....Cureoglu S.	2017
5	Early Postoperative Imaging of the Labyrinth by Cone Beam CT After Stapes Surgery for Otosclerosis With Correlation to Audiovestibular Outcome. ( 28068300 )	Vandevoorde A....Ayache D.	2017
6	Deterioration of Vestibular Cells in Labyrinthitis. ( 27881797 )	Kaya S....Cureoglu S.	2017
7	Blood-Labyrinth Barrier Permeability in MeniA"re Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI. ( 27256854 )	Pakdaman M.N....Sepahdari A.R.	2016
8	Nystagmus in patients with unilateral acute otitis media complicated by serous labyrinthitis. ( 26797398 )	Kim C.H....Shin J.E.	2016
9	Quantitative Assessment of Cochlear Histopathologic Findings in Patients With Suppurative Labyrinthitis. ( 26987015 )	Kaya S....Cureoglu S.	2016
10	Labyrinthitis ossificans after meningitis: Superiority of high-resolution magnetic resonance imaging in demonstration of disease extent compared to high-resolution computed tomography. ( 27114680 )	Vyas S....Khandelwal N.	2016
11	Pathologic Findings of the Cochlea in Labyrinthitis Ossificans Associated with the Round Window Membrane. ( 27221575 )	Kaya S....Cureoglu S.	2016
12	Suppurative labyrinthitis associated with otitis media: 26 years' experience. ( 26718959 )	MaranhALo A.S....Penido N.d.e. .O.	2016
13	Pneumolabyrinth with Labyrinthitis as the Suspected Cause. ( 27115607 )	Nomura K....Himi T.	2016
14	Cochlear changes in serous labyrinthitis associated with silent otitis media: A human temporal bone study. ( 26954857 )	Kaya S....Cureoglu S.	2016
15	Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. ( 25738715 )	Khoo J.N....Tan T.Y.	2015
16	Cortical hot spots and labyrinths: why cortical neuromodulation for episodic migraine with aura should be personalized. ( 25798103 )	Dahlem M.A....Kurths J.	2015
17	Rapidly Destructive Autoimmune Labyrinthitis Associated With Ulcerative Colitis. ( 26385058 )	Hwang M....Zuccoli G.	2015
18	The Impact of Postmeningitic Labyrinthitis Ossificans on Speech Performance After Pediatric Cochlear Implantation. ( 26536413 )	Liu C.C....Isaacson B.	2015
19	HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. ( 25724219 )	Acharya P....Kwong P.D.	2015
20	Labyrinthitis Ossificans: On the Mechanism of Perilabyrinthine Bone Remodeling. ( 25757630 )	Bloch S.L....Friis M.	2015
21	Refractory Positional Vertigo With Apogeotropic Horizontal Nystagmus After Labyrinthitis: Surgical Treatment and Identification of Dysmorphic Ampullae. ( 26208126 )	Ahmed S....Telian S.A.	2015
22	Membrane Stress in the Human Labyrinth and Meniere Disease: A Model Analysis. ( 26491481 )	Pender D.J.	2015
23	Three-dimensional cone beam computed tomography imaging of the membranous labyrinth in patients with Meniere's disease. ( 25220723 )	Yamane H....Imoto T.	2014
24	Longitudinal assessment of endolymphatic hydrops with contrast-enhanced magnetic resonance imaging of the labyrinth. ( 24770407 )	Jerin C....GA1rkov R.	2014
25	The incidence of tympanogenic labyrinthitis ossificans. ( 25075947 )	Lin H.Y....Lin H.C.	2014
26	PAN's Labyrinth: Molecular Biology of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) PAN RNA, a Multifunctional Long Noncoding RNA. ( 25375885 )	Rossetto C.C....Pari G.S.	2014
27	Bilateral sensorineural hearing loss and labyrinthitis ossificans secondary to neurosarcoidosis. ( 25189997 )	Dhanjal H....Irving R.M.	2014
28	Clinical outcome after cochlear implantation in patients with unilateral hearing loss due to labyrinthitis ossificans. ( 23921941 )	Hassepass F....Arndt S.	2013
29	Immunohistochemical localization of I+2-adrenergic receptors in the neonatal rat cochlea and the vestibular labyrinth. ( 23975628 )	Cai J....Wang H.	2013
30	High-resolution 3-D T2-weighted imaging in the diagnosis of labyrinthitis ossificans: emphasis on subtle cochlear involvement. ( 23843131 )	Booth T.N....Isaacson B.	2013
31	A rat in the labyrinth of anorexia nervosa: contributions of the activity-based anorexia rodent model to the understanding of anorexia nervosa. ( 23354987 )	Gutierrez E.	2013
32	Labyrinthitis ossificans in a cochlear implant patient with Usher syndrome. ( 23455060 )	Ruiz A.P....Garcia Gomez J.M.	2013
33	The channel-activating protease CAP1/Prss8 is required for placental labyrinth maturation. ( 23405214 )	Hummler E....Charles R.P.	2013
34	Tuberculous otitis media with facial paralysis combined with labyrinthitis. ( 24653900 )	Hwang G.H....Choi J.	2013
35	Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? ( 23930669 )	Lazzeri S....Bocci G.	2013
36	Geometrical and volume changes of the membranous vestibular labyrinth in guinea pigs with endolymphatic hydrops. ( 23817074 )	Wu C....Dai P.	2013
37	End-stage labyrinthitis with extensive erosion of the bony labyrinth. ( 22377652 )	Lao Z....Cheng Y.S.	2012
38	Acute labyrinthitis secondary to aural tick infestation. ( 23077807 )	Shibghatullah A.H....Mohamad I.	2012
39	Herniation of the membranous labyrinth into the horizontal semicircular canal is correlated with impaired caloric response in MAcniA"re's disease. ( 22918115 )	GA1rkov R....Krause E.	2012
40	Intracranial dermoid cyst ruptured into the membranous labyrinth causing sudden sensorineural hearing loss: CT and MR imaging findings. ( 21920864 )	Koh Y.C....Park H.J.	2012
41	Maternal protein restriction regulates IGF2 system in placental labyrinth. ( 22201967 )	Gao H....Yallampalli C.	2012
42	Apoptosis of the fibrocytes type 1 in the spiral ligament and blood labyrinth barrier disturbance cause hearing impairment in murine cerebral malaria. ( 22297132 )	Schmutzhard J....Lackner P.	2012
43	Endolymphatic hydrops and blood-labyrinth barrier in MAcniA"re's disease. ( 21198346 )	Tagaya M....Nakashima T.	2011
44	Effect of Ginkgo biloba extract on endotoxin-induced labyrinthitis. ( 21592590 )	Jang C.H....Kang S.I.	2011
45	Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. ( 21526906 )	Esaki S....Murakami S.	2011
46	Radiology quiz case 2. Labyrinthitis ossificans secondary to suppurative labyrinthitis. ( 21422319 )	Page N....Kearns D.	2011
47	Deafness due to haemorrhagic labyrinthitis and a review of relapses in Streptococcus suis meningitis. ( 20358139 )	Tan J.H....Seet C.S.	2010
48	Labyrinthitis ossificans secondary to autoimmune inner ear disease: a previously unreported condition. ( 20416474 )	Benson A.G.	2010
49	Labyrinthitis ossificans. ( 19300296 )	Xu H.X....Paparella M.M.	2009
50	Endolymphatic hydrops of the labyrinth visualized on noncontrast MR imaging: a case report. ( 19336989 )	Naganawa S....Nakashima T.	2009

Sources

Genes for Labyrinthitis

Genes related to Labyrinthitis (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CRLF1	Cytokine Receptor Like Factor 1	Protein Coding	16.75	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	IL10RA	Interleukin 10 Receptor Subunit Alpha	Protein Coding	15.52	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	NCS1	Neuronal Calcium Sensor 1	Protein Coding	15.05	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	IGBP1	Immunoglobulin Binding Protein 1	Protein Coding	14.92	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	HINT1	Histidine Triad Nucleotide Binding Protein 1	Protein Coding	14.83	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	HEY2	Hes Related Family BHLH Transcription Factor With YRPW Motif 2	Protein Coding	14.81	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Labyrinthitis

Sources

Expression for Labyrinthitis

Search GEO for disease gene expression data for Labyrinthitis.

Sources

Pathways for Labyrinthitis

Sources

GO Terms for Labyrinthitis

Sources

Sources for Labyrinthitis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia